Illumina Drops Below $51 Offer on Concern Roche Will Walk

Illumina Inc. (ILMN), which has twice rejected unsolicited takeover bids from Roche Holding AG (ROG), fell below the $51-a-share current offer as investors grew concerned that the Swiss drugmaker would abandon the deal.

Illumina dropped 5.8 percent to $49.51 at 4 p.m. New York time in the biggest decline for the San Diego-based company since October. Roche raised its offer on March 29 to $51 a share, or about $6.7 billion, from $44.50 in January. It was the first time the shares dipped below the bid price.

The current offer is “more than adequate to serve as a basis” to start talks and “is full, fair and extremely attractive by every conceivable financial metric,” Roche, based in Basel, Switzerland, said today in a statement. The drugmaker won’t raise the bid without starting talks with Illumina, Roche Chief Executive Officer Severin Schwan told analysts and investors on a conference call.

“There is no reason for us, whatsoever, to increase our offer unless we get into negotiations,” Schwan said. “And so far, this is not the case.”

Illumina’s gene-mapping technology may help Roche, the world’s biggest maker of cancer drugs, tailor medicines to individual patients. A spokesman for Illumina declined to comment today.

“The concern is the possibility that Roche may just say, ‘We don’t want to deal with this anymore,’” said Les Funtleyder, a fund manager who helps oversee $100 million, including Illumina shares, at Miller Tabak & Co. “That Roche might actually be serious about walking away.”

To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.